John P. Sabo

1.1k total citations
34 papers, 919 citations indexed

About

John P. Sabo is a scholar working on Infectious Diseases, Virology and Hepatology. According to data from OpenAlex, John P. Sabo has authored 34 papers receiving a total of 919 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Infectious Diseases, 12 papers in Virology and 12 papers in Hepatology. Recurrent topics in John P. Sabo's work include HIV/AIDS drug development and treatment (21 papers), HIV Research and Treatment (12 papers) and Hepatitis C virus research (12 papers). John P. Sabo is often cited by papers focused on HIV/AIDS drug development and treatment (21 papers), HIV Research and Treatment (12 papers) and Hepatitis C virus research (12 papers). John P. Sabo collaborates with scholars based in United States, Germany and Canada. John P. Sabo's co-authors include Thomas R. MacGregor, Michael Lamson, Joseph Pav, Susan E. Hattox, Paul Riska, James J. Keirns, Robert J. Eckner, A. S. Rosenthal, V J Merluzzi and M. T. SKOOG and has published in prestigious journals such as Journal of Biological Chemistry, Clinical Infectious Diseases and Journal of Applied Physiology.

In The Last Decade

John P. Sabo

34 papers receiving 879 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John P. Sabo United States	16	555	374	150	136	134	34	919
C.P.W.G.M. Verwey-van Wissen Netherlands	21	590 1.1×	347 0.9×	133 0.9×	74 0.5×	186 1.4×	34	1.1k
Robin DiFrancesco United States	18	538 1.0×	298 0.8×	79 0.5×	101 0.7×	204 1.5×	53	968
Paul Savina United States	14	525 0.9×	292 0.8×	63 0.4×	123 0.9×	144 1.1×	22	742
Kristel M. L. Crommentuyn Netherlands	16	661 1.2×	334 0.9×	76 0.5×	208 1.5×	246 1.8×	21	864
John Tjia United Kingdom	17	725 1.3×	452 1.2×	332 2.2×	203 1.5×	236 1.8×	23	1.3k
Deirdre Egan United Kingdom	15	730 1.3×	356 1.0×	100 0.7×	199 1.5×	223 1.7×	26	955
Gerry Rhodes United States	11	434 0.8×	273 0.7×	67 0.4×	80 0.6×	90 0.7×	21	709
Caroline Solas France	23	920 1.7×	430 1.1×	93 0.6×	208 1.5×	162 1.2×	94	1.5k
Rubin Lubomirov Spain	13	374 0.7×	239 0.6×	162 1.1×	132 1.0×	128 1.0×	38	717
P.P. Koopmans Netherlands	17	617 1.1×	385 1.0×	64 0.4×	56 0.4×	124 0.9×	34	986

Countries citing papers authored by John P. Sabo

Since Specialization

Citations

This map shows the geographic impact of John P. Sabo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John P. Sabo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John P. Sabo more than expected).

Fields of papers citing papers by John P. Sabo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John P. Sabo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John P. Sabo. The network helps show where John P. Sabo may publish in the future.

Co-authorship network of co-authors of John P. Sabo

This figure shows the co-authorship network connecting the top 25 collaborators of John P. Sabo. A scholar is included among the top collaborators of John P. Sabo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John P. Sabo. John P. Sabo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yong, Chan‐Loi, Joseph Gathe, Catherine Orrell, et al.. (2017). Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection. HIV Clinical Trials. 18(5-6). 189–195. 3 indexed citations

Sane, Rucha, et al.. (2015). Contribution of Major Metabolites toward Complex Drug-Drug Interactions of Deleobuvir: In Vitro Predictions and In Vivo Outcomes. Drug Metabolism and Disposition. 44(3). 466–475. 23 indexed citations

Zeuzem, Stefan, Vincent Soriano, Tarik Asselah, et al.. (2014). Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Infection and Advanced Liver Fibrosis or Cirrhosis. Antimicrobial Agents and Chemotherapy. 59(2). 1282–1291. 8 indexed citations

Giaquinto, Carlo, Gabriel Anabwani, Cornelia Feiterna‐Sperling, et al.. (2014). Steady-state Pharmacokinetics of Nevirapine Extended-release Tablets in HIV-1–infected Children and Adolescents. The Pediatric Infectious Disease Journal. 33(7). e173–e179. 5 indexed citations

Sabo, John P., Jens Kort, Manuel Haschke, et al.. (2014). Clinical Assessment of Potential Drug Interactions of Faldaprevir, a Hepatitis C Virus Protease Inhibitor, With Darunavir/Ritonavir, Efavirenz, and Tenofovir. Clinical Infectious Diseases. 59(10). 1420–1428. 5 indexed citations

Aslanyan, Stella, et al.. (2011). Effects of Tipranavir, Darunavir, and Ritonavir on Platelet Function, Coagulation, and Fibrinolysis in Healthy Volunteers. Current HIV Research. 9(4). 237–246. 5 indexed citations

Garraffo, R., J. Durant, Nicolas Rouyrre, et al.. (2011). Effect of Tipranavir/Ritonavir Combination on the Pharmacokinetics of Tadalafil in Healthy Volunteers. The Journal of Clinical Pharmacology. 51(7). 1071–1078. 15 indexed citations

Dumond, Julie B., Manoli Vourvahis, Nardin Rezk, et al.. (2010). A Phenotype–Genotype Approach to Predicting CYP450 and P-Glycoprotein Drug Interactions With the Mixed Inhibitor/Inducer Tipranavir/Ritonavir. Clinical Pharmacology & Therapeutics. 87(6). 735–742. 48 indexed citations

Goebel, Frank D., et al.. (2010). Pharmacokinetic Characterization of Three Doses of Tipranavir Boosted with Ritonavir on Highly Active Antiretroviral Therapy in Treatment-Experienced HIV-1 Patients. HIV Clinical Trials. 11(1). 28–38. 2 indexed citations

10.

Bruce, R. Douglas, Frederick L. Altice, David E. Moody, et al.. (2009). Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug and Alcohol Dependence. 105(3). 234–239. 18 indexed citations

11.

Haas, Dorothea, et al.. (2008). Lack of a pharmacokinetic effect between steady-state tipranavir/ritonavir (TPV/r) and single-dose valacyclovir in healthy volunteers. 46th Annual Meeting. 3 indexed citations

12.

Gathe, Joseph, Gerald Pierone, Peter J. Piliero, et al.. (2007). Efficacy And Safety of Three Doses of Tipranavir Boosted with Ritonavir in Treatment-Experienced HIV Type 1-Infected Patients. AIDS Research and Human Retroviruses. 23(2). 216–223. 19 indexed citations

13.

Raffi, François, Manuel Battegay, Stefano Rusconi, et al.. (2007). Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST. AIDS. 21(14). 1977–1980. 18 indexed citations

14.

Mukwaya, Geoffrey, Thomas R. MacGregor, David Hoelscher, et al.. (2005). Interaction of Ritonavir-Boosted Tipranavir with Loperamide Does Not Result in Loperamide-Associated Neurologic Side Effects in Healthy Volunteers. Antimicrobial Agents and Chemotherapy. 49(12). 4903–4910. 47 indexed citations

15.

MacGregor, Thomas R., et al.. (2004). Pharmacokinetic Characterization of Different Dose Combinations of Coadministered Tipranavir and Ritonavir in Healthy Volunteers. HIV Clinical Trials. 5(6). 371–382. 55 indexed citations

16.

Rašković, Aleksandar, et al.. (2002). The effect of celery and parsley juices on pharmacodynamic activity of drugs involving cytochrome P450 in their metabolism. European Journal of Drug Metabolism and Pharmacokinetics. 27(3). 153–156. 34 indexed citations

17.

Sabo, John P., Michael Lamson, G Leitz, Chan‐Loi Yong, & Thomas R. MacGregor. (2000). Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection. PubMed. 2(1). 1–8. 49 indexed citations

18.

Lamson, Michael, John P. Sabo, Thomas R. MacGregor, et al.. (1999). Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers. Biopharmaceutics & Drug Disposition. 20(6). 285–291. 53 indexed citations

19.

Riska, Paul, Michael Lamson, Thomas R. MacGregor, et al.. (1999). Disposition and Biotransformation of the Antiretroviral Drug Nevirapine in Humans. Drug Metabolism and Disposition. 27(8). 895–901. 174 indexed citations

20.

Yokel, Robert A., et al.. (1981). Acute toxicity of latex microspheres. Toxicology Letters. 9(2). 165–170. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact